Switching PD-1 to BRAF + MEK inhibition improves recurrence-free survival in patients receiving a second course of adjuvant melanoma therapy.

ABSTRACT:

Background

PD-1 or BRAF + MEK inhibition is considered the current gold standard in adjuvant melanoma therapy. Little is known if, after the recurrence of the disease and surgery, a second course of adjuvant therapy might be beneficial.

Methods

A multicenter, retrospective study investigating a second course of adjuvant therapy after recurrence and surgery in stage III-IV melanoma patients. Patients received nivolumab (NIV), pembrolizumab (PEM) or dabrafenib plus trametinib (D + T) between 01/2017 and 10/2021. The primary endpoint was 12-month recurrence-free survival (RFS2). Further analyses included descriptive and correlative statistics.

Results

Sixty-six patients from 22 centers in Germany, Austria and Switzerland were included. Thirty-two patients received D + T

SUBMITTER: Schumann K 

PROVIDER: S-EPMC12553123 | biostudies-literature | 2025 Nov

REPOSITORIES: biostudies-literature